# TAVALISSE
> **NDA209299** · New Drug Application · Sponsor: RIGEL PHARMS · Approved 2018-04-17
## Drug
- **FDA Application Number:** NDA209299
- **Application type:** New Drug Application
- **Brand name:** TAVALISSE
- **Generic name:** FOSTAMATINIB
- **Active ingredients:** FOSTAMATINIB DISODIUM
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** RIGEL PHARMS
- **Manufacturer:** Rigel Pharmaceuticals, Inc.
- **First approval:** 2018-04-17
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299)
---
*AI Analytics · CC0 1.0*